ICH Topic M 4 Common Technical Document for the Registration of Pharmaceuticals for Human Use Organisation CTD. Step 5
|
|
- Buddy Hardy
- 6 years ago
- Views:
Transcription
1 European Medicines Agency February 2004 CPMP/ICH/2887/99 ICH Topic M 4 Common Technical Document for the Registration of Pharmaceuticals for Human Use Organisation CTD Step 5 COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE: ORGANISATION OF COMMON TECHNICAL DOCUMENT (CPMP/ICH/2887/99) TRANSMISSION TO CPMP July 2000 RELEASE FOR CONSULTATION July 2000 DEADLINE FOR COMMENTS September 2000 TRANSMISSION TO CPMP AND RELEASE FOR INFORMATION November 2000 NUMBERING AND SECTION HEADERS EDITED September 2002 TRANSMISSION TO CPMP AND RELEASE FOR INFORMATION February 2003 DATE FOR IMPLEMENTATION July 2003 REVISION OF GRANULARITY DOCUMENT (ANNEX) November 2003 TRANSMISSION TO CPMP AND RELEASE FOR INFORMATION November 2003 RELEASE OF CORRECTION FOR INFORMATION February 2004 Note: The sequence of M4 Common Technical Document for the Registration of Pharmaceuticals for Human Use is: M4 - Organisation of the Common Technical Document M4 Quality - Quality overall summary and CTD Quality M4 Safety - Nonclinical Summaries and Organisation of Module 4 M4 Efficacy - Clinical overview, clinical summary, sample tables for clinical summary and module V 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) Fax (44-20) mail@emea.eu.int EMEA 2006 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged
2 The document as presented may be subject to further editorial changes and is for information only. Details on how to prepare a submission dossier based on the CTD format including information on the content of Module I are included in the revision of the Notice to Applicants. EMEA
3 ICH M4 - COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE: ORGANISATION OF THE COMMON TECHNICAL DOCUMENT (Numbering and Section Headers have been edited for consistency and use in e-ctd as agreed at the Washington DC Meeting, September 11-12, 2002) OBJECTIVE OF THE GUIDELINE This guideline presents the agreed upon common format for the preparation of a wellstructured Common Technical Document for applications that will be submitted to regulatory authorities. A common format for the technical documentation will significantly reduce the time and resources needed to compile applications for registration of human pharmaceuticals and will ease the preparation of electronic submissions. Regulatory reviews and communication with the applicant will be facilitated by a standard document of common elements. In addition, exchange of regulatory information between Regulatory Authorities will be simplified. BACKGROUND Through the ICH process, considerable harmonisation has been achieved among the three regions in the technical requirements for the registration of pharmaceuticals for human use. However, until now, there has been no harmonisation of the organisation of the registration documents. Each region has its own requirements for the organisation of the technical reports in the submission and for the preparation of the summaries and tables. In Japan, the applicants must prepare the GAIYO, which organises and presents a summary of the technical information. In Europe, Expert Reports and tabulated summaries are required, and written summaries are recommended. The U.S. FDA has guidance regarding the format and content of the New Drug Application. To avoid the need to generate and compile different registration dossiers, this guideline describes a format for the Common Technical Document that will be acceptable in all three regions. SCOPE OF THE GUIDELINE This guideline primarily addresses the organisation of the information to be presented in registration applications for new pharmaceuticals (including biotechnology-derived products). This guideline is not intended to indicate what studies are required. It merely indicates an appropriate format for the data that have been acquired. Applicants should not modify the overall organisation of the Common Technical Document as outlined in the guideline. However, in the Nonclinical and Clinical Summaries, applicants can modify individual formats if needed to provide the best possible presentation of the technical information, in order to facilitate the understanding and evaluation of the results. GENERAL PRINCIPLES Throughout the Common Technical Document, the display of information should be unambiguous and transparent, in order to facilitate the review of the basic data and to help a reviewer become quickly oriented to the application contents. Text and tables should be prepared using margins that allow the document to be printed on both A4 paper (E.U. and Japan) and 8.5 x 11 paper (U.S.). The left-hand margin should be sufficiently large that information is not obscured by the method of binding. Font sizes for text and tables should be of a style and size that are large enough to be easily legible, even after photocopying. Times New Roman, 12-point font, is recommended for narrative text. Every page should be numbered, according to the granularity document. Acronyms and abbreviations should be defined the first time they are used in each module. References should be cited in accordance EMEA
4 with the current edition of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, International Committee of Medical Journal Editors (ICMJE) 1. ORGANISATION OF THE COMMON TECHNICAL DOCUMENT The Common Technical Document is organized into five modules. Module 1 is region specific. Modules 2, 3, 4, and 5 are intended to be common for all regions. Conformance with this guideline should ensure that these four modules are provided in a format acceptable to the regulatory authorities. Module 1. Administrative Information and Prescribing Information This module should contain documents specific to each region; for example, application forms or the proposed label for use in the region. The content and format of this module can be specified by the relevant regulatory authorities. Module 2. Common Technical Document Summaries Module 2 should begin with a general introduction to the pharmaceutical, including its pharmacologic class, mode of action, and proposed clinical use. In general, the Introduction should not exceed one page. Module 2 should contain 7 sections in the following order : CTD Table of Contents CTD Introduction Quality Overall Summary Nonclinical Overview Clinical Overview Nonclinical Written and Tabulated Summaries Clinical Summary The organisation of these summaries is described in Guidelines for M4Q, M4S, and M4E. Module 3. Quality Information on Quality should be presented in the structured format described in Guideline M4Q. Module 4. Nonclinical Study Reports The nonclinical study reports should be presented in the order described in Guideline M4S. Module 5. Clinical Study Reports The human study reports and related information should be presented in the order described in Guideline M4E. The overall organisation of the Common Technical Document is presented on the following pages. 1 The first edition of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals was conceived by the Vancouver Group and was published in EMEA
5 Diagrammatic Representation of the Organization of the ICH CTD Common Technical Document Module 1 Regional Administrative Information Submission T of C Not part of the CTD CTD Table of Contents 2.1 Module 2 CTD Introduction 2.2 Quality Overall Summary 2.3 Nonclinical Overview Nonclinical 2.4 Written and Tabulated Summaries 2.6 Clinical Overview 2.5 Clinical Summary 2.7 CTD Module 3 Module 4 Module 5 Quality T of C Nonclinical Study Reports T of C Clinical Study Reports T of C EMEA
6 ORGANISATION OF THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Module 1: Administrative Information and Prescribing Information 1.1. Table of Contents of the Submission Including Module Documents Specific to Each Region (for example, application forms, prescribing information) Module 2: Common Technical Document Summaries 2.1 Common Technical Document Table of Contents (Modules 2-5) 2.2 CTD Introduction 2.3 Quality Overall Summary 2.4 Nonclinical Overview 2.5 Clinical Overview 2.6 Nonclinical Written and Tabulated Summaries Pharmacology Pharmacokinetics Toxicology 2.7 Clinical Summary Biopharmaceutic Studies and Associated Analytical Methods Clinical Pharmacology Studies Clinical Efficacy Clinical Safety Literature References Synopses of Individual Studies Module 3: Quality 3.1 Table of Contents of Module Body of Data 3.3 Literature References Module 4: Nonclinical Study Reports 4.1 Table of Contents of Module Study Reports 4.3 Literature References Module 5: Clinical Study Reports 5.1 Table of Contents of Module Tabular Listing of All Clinical Studies 5.3 Clinical Study Reports 5.4 Literature References EMEA
7 ANNEX : Granularity Document The CTD specifies many section headings and numbers. Could guidance be provided for all modules on headings in relation to document location and the section headings within those documents? Could guidance also be provided on where in the CTD and ectd multiple documents can be located in the hierarchy? As a consequence of this definition could guidance be given on how documents should be paginated and on what the module Table of Contents should therefore include? Definition of a Document A document is defined for a paper submission as a set of pages, numbered sequentially and divided from other documents by a tab (see Document Pagination and Segregation section of this Annex). A document can be equated to a file for an electronic submission. The granularity of the paper and electronic submissions should be equivalent, although if a paper submission is updated to be an electronic submission, some changes in granularity could be introduced to facilitate on-going lifecycle management. In an electronic submission, a new file starts at the same point at which in a paper submission, a tab divides the documents. In deciding whether one or more documents or files are appropriate, it should be considered that once a particular approach has been adopted, the same approach should be used throughout the life of the dossier since it is the intention that replacement documents/files be provided when information is changed. The following tables describe the levels in the CTD/eCTD hierarchy at which documents/files should be placed and whether single or multiple documents are appropriate at each point. This describes all sections of a CTD/eCTD but for individual submissions all sections might not be applicable. EMEA
8 Module 2 Module The TOC is only called for in the paper version of the CTD; there is no entry needed for the ectd Note 1 Introduction 2.3.S Note S S S S S S S P Note P P P P P P P P A 2.3.A A A R Note Key Documents rolled up to this level are not considered appropriate One document may be submitted at this level Note 1 : Optionality of granularity for the Quality Overall Summary is provided in order to accommodate different levels of complexity of products. The applicant can choose the level at which the QOS is managed. Note 2 : One document should be submitted for each drug substance Note 3 : For a drug product supplied with reconstitution diluent(s), the information on the diluent(s) should be provided in a separate part P document Note 4 : One document for each indication should be submitted, although closely related indications can be within a single document EMEA
9 Module 3 Module 3 Note The TOC is only called for in the paper version of the CTD; there is no entry needed for the ectd S Note S S S S P Note S S S S S S P P S S S S S S S S S S S S S S S S P.2.1 Note P.2.2 Note P P P P P P P P P P P P P P P P P P P P P P P P P.5.6 EMEA
10 3.2.A 3.2.P P A A A R Note One file per reference Note P P P.8.3 Key Documents rolled up to this level are not considered appropriate One or multiple documents can be submitted at this level Note 1 : In choosing the level of granularity for this Module, the applicant should consider that, when relevant information is changed at any point in the product's lifecycle, replacements of complete documents/files should be provided in the CTD and ectd. Note 2 : For a drug product containing more than one drug substance, the information requested for part S should be provided in its entirety for each drug substance. Note 3 : For a drug product supplied with reconstitution diluent(s), the information on the diluent(s) should be provided in a separate part P, as appropriate. Note 4 : The lower level of headings included in CTD-Q at this point are unlikely to be individual documents or files. Note 5 : Refer to regional guidances. Note 6 : Literature References should be listed in the tables of contents. EMEA
11 Module 4 Module The TOC is only called for in the paper version of the CTD; there is no entry needed for the ectd Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note One file per reference Note Studies Note Studies Note Studies Note Studies Note Studies Note 1 Key Documents rolled up to this level are not considered appropriate One or multiple documents can be submitted at this level Note 1 : Typically, a single document should be provided for each study report included in Module 4. However, where the study report is large, (e.g., a carcinogenicity study), the applicant can choose to submit the report as more than one document. In this case, the text portion of the report should be one document and the appendices can be one or more documents. In choosing the level of granularity for these reports, the applicant should consider that, when relevant information is changed at any point in the product's lifecycle, replacements of complete documents/files should be provided. Note 2 : Literature References should be listed in the tables of contents. EMEA
12 Module 5 Module The TOC is only called for in the paper version of the CTD; there is no entry needed for the ectd Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Studies Note Note Studies Note Studies Note Studies Note Studies Note Studies Note One file per reference Note 3 Key Documents rolled up to this level are not considered appropriate One document can be submitted at this level One or multiple documents can be submitted at this level Note 1 : The applicants should ordinarily provide the study reports as multiple documents (a synopsis, a main body of the study report and appropriate appendices). Appendices should be organized in accordance with the ICH E3 guideline, which describes the content and format of the clinical study report. In choosing the level of granularity for reports the applicant should consider that, when relevant information is changed at any point in the product's lifecycle, replacements of complete documents/files should be provided. Note 2 : For applications in support of more than one indication, this section should be repeated for each indication. Note 3 : Literature References should be listed in the tables of content. Document Pagination and Segregation Every document should be numbered starting at page one, except for individual literature references, where the existing journal page numbering is considered sufficient. Applicants need not display the number as '1 of n' where n is the total number of pages in the document. Additionally, all pages of a document should include a unique header or footer that briefly identifies its subject matter. In a paper-based drug submission, a similar identifier should be used on a tab that precedes the document, to facilitate finding that document within the dossier. An abbreviation of the full section number and title can be used. EMEA
13 If a section contains more than one document, a specific Table of Contents for that section can be included to identify the chronology and titles of the documents contained therein, e.g. Tab with 3.2.S.4.2 Analytical Procedures o Table of Contents, listing the title of Procedure A, Procedure B, Procedure C Tab with 3.2.S.4.2 Procedure A ; o Procedure A (i.e. document, page 1-n) Tab with 3.2.S.4.2 Procedure B ; o Procedure B (i.e. document, page 1-n) Tab with 3.2.S.4.2 Procedure C ; o Procedure C (i.e. document, page 1-n) If a section contains only a single document (e.g. 3.2.S.1.1 Nomenclature), only a tab identified by 3.2.S.1.1 Nomenclature should precede the document. Section Numbering within Documents In order to avoid 5 th, 6 th etc. level subheading numbering (e.g ) within a document, the applicant can use a shortened numbering string. In this case, the document number and the name (e.g Toxicology Written Summary) should appear in page headers or footers and then section numbering within the document can be used, for example, 1, 1.1, 2, 3, 3.1, 3.2 etc. Use of the full numbering string (e.g ) is also considered acceptable. Table of Contents Formatting Module 2 The 2.1 CTD Table of Contents should go down to the third (e.g. 2.3.S) or fourth (e.g. 2.3.S.1) level, depending on how a document is defined for the Quality Overall Summary. (See Definition of a document for Module 2.) Module 3 The Table of Contents provided under 3.1 should cover the high-level section numbering, the associated section heading and the Volume number in the order that they appear in the drug submission. This Table of Contents would be used to identify the contents of Module 3 as defined in the M4Q guideline. It should go down to the fifth level only (e.g. 3.2.P.2.1). Note that additional subsections and subheadings are defined in the M4Q guideline beyond this level (e.g. under 3.2.P.2) and this formatting should be used within the dossier, despite not being included in the 3.1 Table of Contents. The lower level Table of Contents described under Document Pagination and Segregation should be excluded from the 3.1 Table of Contents. At the applicant s discretion, a Table of Contents can also be included for a particular section that contains multiple documents, in order to identify the chronology and the document subject matter. If there is a desire to introduce additional headers or subsection numbering beyond those which are defined in the M4Q guideline, these should only be included within a document and should be created neither as a separate document nor as a new subsection. In this case, a specific Table of Contents for that document can be included to identify the chronology and titles of the subsections contained therein. These documents and subsections should not appear in the 3.1 Table of Contents. Furthermore, additional attachments or appendices should not be incorporated into this formatting, except as a document under a section where multiple documents might be provided. In this case, a cross-reference should be made within the relevant section to the attached or appended document. If there is a desire to append or attach additional information to a section that is comprised of only one document, this information should be incorporated within that document. All Table of Contents title entries should either correspond to heading names and section numbering as defined in the M4Q guideline or to identifiers appearing on tabs (for a paper- EMEA
14 based drug submission only), preferably by their full title, which should easily identify any abbreviated title that might be used on the corresponding tab. The Table of Contents should not specify any page numbers. Literature References should be listed in a Table of Contents specific for this section. Module 4 The Table of Contents for Module 4 should include all of the numerical items listed in the CTD guideline in order to identify all of the important components of the application (for example, Fertility and early embryonic development) and should continue down to at least the level of the study report. Thus each study report should be identified in the table of contents. The sections of a study report could be identified in the Module 4 Table of Contents of the dossier or only in the Table of Contents of the individual study report. Illustration of part of the Module 4 Table of Contents Repeat-Dose Toxicity Study aa-aaa: 30 day repeat dose toxicity study with Drug C in rat Study bb-bbb: 6 month repeat dose toxicity study with Drug C in rat Study cc-ccc: 30 day repeat dose toxicity study with Drug C in dog Study dd-ddd: 6 month repeat dose toxicity study with Drug C in dog Genotoxicity In vitro Study ee-eee: Ames test with Drug C etc. Module 5 The Table of Contents for Module 5 should include all of the numerical items listed in the CTD guideline in order to identify all of the important components of the application (for example, Placebo Controlled Trials) and should continue down to at least the level of the clinical study report. Thus each clinical study report should be identified in the table of contents. The sections of a clinical study report (E3) could be identified in the Module 5 Table of Contents of the dossier or only in the Table of Contents of the individual clinical study report. Illustration of part of the Module 5 Table of Contents Indication Z - Reports of Efficacy and Safety Studies Indication Z - Study Reports of Controlled Clinical Trials Pertinent to the Claimed Indication Indication Z - Placebo Controlled Trials Study xx-xxx: A double blind, placebo-controlled trial of Drug A in Indication Z Study yy-yyy: A double blind Indication Z - Active Controlled Trials Study zz-zzz: A double blind, active controlled trial of Drug A vs. Drug C in Indication Z Indication Q - Reports of Efficacy and Safety Studies Indication Q - Study Reports of Controlled Clinical Trials Pertinent to the Claimed Indication etc. EMEA
MEDICINES CONTROL COUNCIL
CMs ZACTD MEDICINES CONTROL COUNCIL COMPLEMENTARY MEDICINES - USE OF THE ZA-CTD FORMAT IN THE PREPARATION OF A REGISTRATION APPLICATION This guideline is intended to provide recommendations to applicants
More information1. Document Control 2. Change Record Version Date Author(s) Comments 3. Reviewers Version Name Organisation 4. Distribution Version Date Name Status
for the paper submission of regulatory information in support of a marketing authorisation application when using the Electronic Common Technical Document ( ectd ) as the source submission. V1.0 February
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) GUIDELINE ON REQUIREMENTS FOR PLASMA MASTER FILE (PMF) CERTIFICATION
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 26 February 2004 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) GUIDELINE ON REQUIREMENTS
More informationComplementary Medicines. Registration: Process, Format and Requirements
Complementary Medicines Registration: Process, Format and Requirements Feb 2014 Estelle Taute Overview Registration process Dossier format Requirements - Guidelines - Technical Quality, Safety, Efficacy
More informationZambia Medicines Regulatory Authority APPLICATION FOR MARKETING AUTHORISATION OF A MEDICINE FOR HUMAN USE
Zambia Medicines Regulatory Authority APPLICATION FOR MARKETING AUTHORISATION OF A MEDICINE FOR HUMAN USE COMMON TECHNICAL DOCUMENT FORMAT ZAMBIA Module 1 CTD-Modules 2-5 Version 03, April 2015 ZAMBIA
More informationectd : Industry Experience
ectd : Industry Experience SAPRAA - 26 March 2010 Anita Smal Agenda Introduction Experience with MCC pilot project Lessons learnt ectd structure Life cycle Further guidance required from MCC Submission-ready
More information1 2 December esubmissions? 1. How can baseline dossiers support global esubmissions? Disclaimer. What is a baseline submission?
How can baseline dossiers support global Hans van Bruggen www.ectdconsultancy.com How can baseline dossiers support global 1 Disclaimer The views and opinions expressed in the following PowerPoint slides
More informationGuideline on the specifications for provision of an electronic submission (e-submission) for a veterinary medicinal product
Guideline prepared by the TIGes-Vet Version 1.0 June 2009 Guideline on the specifications for provision of an electronic submission (e-submission) for a veterinary medicinal product 1. Introduction This
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL Questions & Answers Implementation of ectd in South Africa This document is intended to provide clarity on guidelines and specifications for applications for the registration
More informationBy Cornelia Wawretchek. The Drug Manufacturer s Guide to Site Master Files
By Cornelia Wawretchek The Drug Manufacturer s Guide to Site Master Files ISBN: 978-3-943267-69-3 A Process Approach to Pharmaceutical Quality Systems A Guide to ICH Q10 Compliance Where a product trademark,
More informationMEDICINES CONTROL COUNCIL
SOUTH AFRICAN COMMON TECHNICAL DOCUMENT MEDICINES CONTROL COUNCIL APPLICATION FOR REGISTRATION OF A MEDICINE South African Module 1 CTD-Modules 2-5 MCC Edition August 2012 South African Common Technical
More informationBiotechnology Industry Organization 1225 Eye Street NW, Suite 400 Washington, DC 20006
Biotechnology Industry Organization 1225 Eye Street NW, Suite 400 Washington, DC 20006 December 22, 2003 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville,
More informationEMA Common Repository: Questions and answers relating to practical and technical aspects of the implementation
November 2016 - updated EMA/243820/2013 EMA Common Repository: Questions and answers relating to practical and technical aspects of the implementation This question and answer document aims to address
More informationGet ready for ectd in South Africa. Current status at MCC
Get ready for ectd in South Africa Current status at MCC E Taute Feb 2013 Overview Background Guidelines, Specifications, Forms ICH ectd Specification V 3.2.2 16-July-2008 2.21 South African Specification
More informationGDUFA s Impact on ectds / Case Study: Implementing PDF Standards
GDUFA s Impact on ectds / Case Study: Implementing PDF Standards GPhA 2015 Fall Technical Conference GDUFA S Impact on ectds GPhA 2015 Fall Technical Conference 1 Introductions Kevin Tompkins Director,
More informationOrientation Material for M8: ectd EWG ectd v4.0 Implementation Package v1.3
Orientation Material for M8: ectd EWG ectd v4.0 Implementation Package v1.3 International Council on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 1 Legal Notice This presentation
More informationICH M8 Expert Working Group. Specification for Submission Formats for ectd v1.1
INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH M8 Expert Working Group Specification for Submission Formats for ectd v1.1 November 10, 2016 DOCUMENT
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH M2 EWG
ICH ectd Specification V 2.0 February 12, 2002 INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH M2 EWG Electronic Common Technical
More informationectd Next Major Release Business Requirements Collation (9-JUN-10) TOPIC Requirement Comment
ICH Req No. ectd Next Major Release Business Requirements Collation (9-JUN-10) TOPIC Requirement Comment ICH001 ICH002 ICH003 ICH004 APPLICATION APPLICATION APPLICATION APPLICATION A regulated product
More informationectd Next Major Release Business Requirements Collation (11 NOV 10) TOPIC Requirement Comment ICH Req No.
ICH Req No. ICH001 ICH002 ICH003 ICH004 ectd Next Major Release Business Requirements Collation (11 NOV 10) TOPIC Requirement Comment A regulated product application may have one or more regulatory activities
More informationPROPOSED DOCUMENT. International Medical Device Regulators Forum
PROPOSED DOCUMENT International Medical Device Regulators Forum Title: Assembly and Technical Guide for IMDRF Table of Contents (ToC) Submissions (ToC-based submissions) Authoring Group: Regulated Product
More informationectd TECHNICAL CONFORMANCE GUIDE
ectd TECHNICAL CONFORMANCE GUIDE Technical Specifications Document This Document is incorporated by reference into the following Guidance Document(s): Guidance for Industry Providing Regulatory Submissions
More informationTips on Creating a Strategy for a CDISC Submission Rajkumar Sharma, Nektar Therapeutics, San Francisco, CA
PharmaSUG 2015 - Paper IB09 Tips on Creating a Strategy for a CDISC Submission Rajkumar Sharma, Nektar Therapeutics, San Francisco, CA ABSTRACT A submission to FDA for an NDA (New Drug Application) or
More informationChange Control Process for European ectd Standards Version 1.1. December 2006
Change Control Process for European ectd Standards Version 1.1 December 2006 Document Control Change Record Version Date Author(s) Comments 0.1 10 September, 2003 Miguel Bley Draft 0.2 11 September, 2003
More information3 September
3 September 2012 Reference: EMA 12007 By e-mail: Silvia.Domingo@ema.europa.eu Dr. Silvia DOMINGO European Medicines Agency 7 Westferry Circus Canary Wharf London E14 4HB, United Kingdom Subject: epmf Database
More informationectd Next Major Version Business Requirements (11-JUN-09)
ICH Req No. ICH01 ICH02 ICH03 ICH04 TOPIC APPLICATION APPLICATION APPLICATION APPLICATION ectd Next Major Version Business Requirements (11-JUN-09) Requirement A regulated product application may have
More informationGuidance for Industry on Providing Regulatory Information in Electronic Format: Non-eCTD electronic Submissions (NeeS) for human medicinal products
Guidance for Industry on Providing Regulatory Information in Electronic Format: Non-eCTD electronic Submissions (NeeS) for human medicinal products This document is published under the auspices of the
More informationENCePP Code of Conduct Implementation Guidance for Sharing of ENCePP Study Data
EMA/409316/2010 Revision 2, dated 14 July 2016 European Network of Centres for Pharmacoepidemiology and Pharmacovigilance ENCePP Code of Conduct Implementation Guidance for Sharing of ENCePP Study Data
More informationGet ready for ectd in South Africa
Get ready for ectd in South Africa Going from CTD to ectd Anita Smal, 14 & 15 February 2013 Agenda The goal Planning Prepare submission ready documents PDFs ectd content planning ectd structure planning
More informationA CMC Reviewer s Perspective on the Quality Overall Summary. Arthur B. Shaw, Ph.D. FDA/CDER/ONDQA FDA DMF Expert June 15, 2010.
A CMC Reviewer s Perspective on the Quality Overall Summary and Module 3 Arthur B. Shaw, Ph.D. FDA/CDER/ONDQA FDA DMF Expert June 15, 2010 Disclaimer The views and opinions expressed in the following PowerPoint
More informationGuidance for electronic submissions for Certificates of Suitability (CEP) applications
CBW/CB PUBLIC DOCUMENT (Level 1) English only/nglais seulement Strasbourg, January 2018 Certification of Suitability to the Monographs of the European Pharmacopoeia Guidance for electronic submissions
More informationMultinational assessment teams
14 July 2017 EMA/486654/2016 Deputy Executive Director Guide for rapporteurs and coordinators 1. Background The multinational assessment team (MNAT) concept allows the option of an assessment team to be
More informationRevision of Technical Conformance Guide on Electronic Study Data Submissions
Notification No. 0824001 August 24, 2016 To: Prefectural Health Department (Bureau) Director of the Advanced Review with Electronic Data Promotion Group, Pharmaceuticals and Medical Devices Agency Revision
More informationSUBMISSION OF COMMENTS ON Guideline on Real Time Release Testing (formerly Guideline on Parametric Release) Draft
26 August 2010 European Medicines Agency 7 Westferry Circus Canary Wharf London E14 4HB United Kingdon Attn: Quality Working Party SUBMISSION OF COMMENTS ON Guideline on Real Time Release Testing (formerly
More informationGuidance for the format and content of the final study report of non-interventional post-authorisation safety studies
23 January 2013 EMA/48663/2013 Patient Health Protection Guidance for the format and content of the final study report of non-interventional post-authorisation safety studies Introduction From 10 January
More informationInstructions for Authors Canadian Journal of Pathology (CJP)
Instructions for Authors Canadian Journal of Pathology (CJP) Canadian Journal of Pathology is a quarterly, peer-reviewed publication. It is published by Clockwork Communications as the agent for Canadian
More informationStudy Data Reviewer s Guide
Revision History Date Study Data Reviewer s Guide Completion Guideline: Nonclinical (nnsdrg) Version Summary V1.1 03 March 2016 1.0 First Public Version: posted for Public Comment 1.1 Update from Public
More informationPre-notification check for type IB Variations 1
Pre-notification check for type IB Variations 1 This pre-notification checklist is aimed at facilitating submission of complete and correct Type IB variation notifications by Marketing Authorisation Holders
More informationDate: May 19, Dear Dr. Domingo,
Date: May 19, 2015 Reference: EMA15003 VIA E-MAIL Dr. Silvia Domingo European Medicines Agency 30 Churchill Place, Canary Wharf London E14 5EU UNITED KINGDOM Silvia.Domingo@ema.europa.eu Dear Dr. Domingo,
More informationThis is the production release of the second iteration of EudraCT 8.1. It includes the following main functional changes:
9 September 2011 EMA/646917/2011 Release notes EudraCT Version: 8.1.1 Goal: Release 8.1 Iteration 2 Release Date: 12/09/11 Environment: Production (Public) Release Contents: This is the production release
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL STANDARDISED PACKAGE INSERTS FOR HUMAN MEDICINES The purpose of this document is to define the criteria for developing standardised package inserts (SPI) and for the use of an
More informationAbout Domestic Implementation of the Electronic File Specifications to Be Included in the ICH Electronic Common Technical Document (ectd) v1.1.
Appendix 2 About Domestic Implementation of the Electronic File Specifications to Be Included in the ICH Electronic Common Technical Document (ectd) v1.1.0 between the Japanese original and the English
More informationRPS/ICH Requirements. sequence number values would need to be unique to each application. principle. 1 of 14
o. ICH01 ectd ext Major Release Business Requirements Collation (12 OV 08) APPLICATIO A regulated product application may have one or LIFECCLE more regulatory activities associated with it RPS 1 included
More informationExample Paper in the ICROMA Format
Example Paper in the ICROMA Format John Smith a, Jan M.P. Jansen a,1, Taro Yamada b a Department of AAA, BBB University of Technology P.O. Box 1111, 2222 GA Delft, The Netherlands 1 E-mail: jansen@aaa.bbb.nl,
More informationesubmission Gateway and Web Client Training on the use of XML delivery files for Veterinary submissions
esubmission Gateway and Web Client Training on the use of XML delivery files for Veterinary submissions Webinar training on v1.0 Presented by Kristiina Puusaari on 3 June 2016 An agency of the European
More informationStandard operating procedure
Standard operating procedure Title: Procedure for liaising between the EMA, the CHMP and the CTFG on the potential CHMP negative opinion, pre-opinion or post-authorisation withdrawal, suspension or revocation
More informationGENERAL ACVIM PROCEEDINGS MANUSCRIPT GUIDELINES 2009 ACVIM Forum & Canadian VMA Convention June 3 June 6, 2009 Montréal, Québec
GENERAL ACVIM PROCEEDINGS MANUSCRIPT GUIDELINES 2009 ACVIM Forum & Canadian VMA Convention June 3 June 6, 2009 Montréal, Québec To: From: ACVIM Forum/Canadian VMA Convention Speakers Dr. Sheila McGuirk,
More informationGuidance for electronic and paper submissions for Certificates of Suitability (CEP) applications
FK/CB PUBLIC DOCUMENT (LEVEL 1) English only/nglais seulement Strasbourg, June 2013 Certification of suitability to Monographs of the European Pharmacopoeia Guidance for electronic and paper submissions
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH M2 EWG
ICH ectd Specification V 3.2 February 04, 2004 INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH M2 EWG Electronic Common Technical
More informationEUROPEAN MEDICINES AGENCY (EMA) CONSULTATION
EUROPEAN MEDICINES AGENCY (EMA) CONSULTATION Guideline on GCP compliance in relation to trial master file (paper and/or electronic) for content, management, archiving, audit and inspection of clinical
More informationectd Practical experiences of the ectd pilot project and way forward
ectd Practical experiences of the ectd pilot project and way forward 26 August 2016 SAPRAA Estelle Taute 1 Overview Pilot Project Specifications & Guidelines Requirements vs Actual Validation issues Lifecycle
More informationManagement of RMP for CAPs in postauthorisation
Management of RMP for CAPs in postauthorisation EMA perspective Presented by Iordanis Gravanis on 9 November 2015 Head of Evaluation Procedures C, Procedure Management (and Committees Support) An agency
More informationUDI Implementation Update. GS1 UK Healthcare Conference - 22 November 2017 John Wilkinson OBE Medicines and Healthcare Products Regulatory Agency
UDI Implementation Update GS1 UK Healthcare Conference - 22 November 2017 John Wilkinson OBE Medicines and Healthcare Products Regulatory Agency 2 Why new European medical device and IVD regulations? Old
More informationWPPD Senior Pharmaceutical Care (PC) Paper Evaluation Student Name:
WPPD Senior Pharmaceutical Care (PC) Paper Evaluation Student Name: First Draft Evaluation by: Date Reviewed: THE SUBMITTED DRAFT FOR REVIEW BY UF EDITORIAL TEAM: is ACCEPTABLE pending final report with
More informationFDA Portable Document Format (PDF) Specifications
Revision History FDA PORTABLE DOCUMENT FORMAT (PDF) SPECIFICATIONS Date Summary of Changes Version 2005-04-08 Initial version 1.0 2008-06-04 Changed Bookmarks and Page 2.0 to Bookmarks Panel and Page in
More informationGuidance for Industry on Providing Regulatory Information in Electronic Format: ectd electronic Submissions
DRAFT FOR TESTING Guidance for Industry on Providing Regulatory Information in Electronic Format: ectd electronic Submissions This document is published under the auspices of the EU Telematic Implementation
More informationPSUR Repository Interactive Q&A
PSUR Repository Interactive Q&A Interactive Q&A session with MAHs on the new functionality provided in release 1.03.00 Presented by Kristiina Puusaari on 10 September 2015 An agency of the European Union
More informationReport of the Working Group on mhealth Assessment Guidelines February 2016 March 2017
Report of the Working Group on mhealth Assessment Guidelines February 2016 March 2017 1 1 INTRODUCTION 3 2 SUMMARY OF THE PROCESS 3 2.1 WORKING GROUP ACTIVITIES 3 2.2 STAKEHOLDER CONSULTATIONS 5 3 STAKEHOLDERS'
More informationEuropean Congress on Thrombosis and Haemostasis Abstract submission guidelines
European Congress on Thrombosis and Haemostasis Abstract submission guidelines Table of contents Introduction The abstract submission guidelines of the ECTH Congress are intended to provide clear instructions
More informationA SAMPLE PAPER SHOWING THE FORMAT REQUIRED FOR YOUR CONTRIBUTION TO THE SAGEEP 2015 PROCEEDINGS. Abstract. Submission Procedure
A SAMPLE PAPER SHOWING THE FORMAT REQUIRED FOR YOUR CONTRIBUTION TO THE SAGEEP 2015 PROCEEDINGS EEGS Annual Meeting Austin, TX USA March 22-26, 2015 Abstract Thank you for your participation in SAGEEP
More informationApplies to: SA Administrative Assistant, SAWP Scientific Secretary and SA secretarial team in Scientific Advice Section
Work instructions Title: Use of scientific advice and protocol assistance database Applies to: SA Administrative Assistant, SAWP Scientific Secretary and SA secretarial team in Scientific Advice Section
More informationExample Paper in the ICROMA Format
Example Paper in the ICROMA Format John Smith a, Jan M.P. Jansen a,1, Taro Yamada b a Department of AAA, BBB University of Technology P.O. Box 1111, 2222 GA Delft, The Netherlands 1 E-mail: jansen@aaa.bbb.nl,
More informationInterested parties (organisations or individuals) that commented on the draft document as released for consultation.
27 February 2014 EMA/659397/2013 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) Submission of comments on Guideline on process validation
More informationCommon Statistical Analysis Plan (SAP) Frequently Asked Questions
Last Updated 4-Nov-2018 Topics 1 Stakeholder Input to Common SAP Template Development... 2 2 Template Content... 2 3 Implementation of the Common SAP template by the Sponsor... 55 4 Updates to the Common
More informationEudraVigilance Components & Functionality Introduction
EudraVigilance Components & Functionality Introduction Training Module EV-M2 This module outlines the EudraVigilance system components and system functionalities An agency of the European Union Content
More informationInstructions/template for preparing your NOLTA manuscript (Ver. 3.02, Aug. 28, 2015)
NOLTA, IEICE Paper Instructions/template for preparing your NOLTA manuscript (Ver. 3.02, Aug. 28, 2015) Name Author1 1a), Name Author2 2, and Name Author3 1 1 Institute of Industrial Science, University
More informationTECHNICAL PAPER FORMAT GUIDE
TECHNICAL PAPER FORMAT GUIDE 1. INTRODUCTION Congratulations on being selected to participate in the 2019 WJTA-IMCA Conference and Expo. Your paper will be published along with others to form a comprehensive
More informationEuropean Medicines Agency Standard Operating Procedure
European Medicines Agency Standard Operating Procedure Title: Procedure to be followed by the EMEA in case of mechanical, programme, electronic or communication failure, which prevents a Sender from generating
More informationGT48232/ME4182 First Progress Report & Presentation (Fall 2016)
GT48232/ME4182 First Progress Report & Presentation (Fall 2016) The report clearly, concisely, and logically documents work to date including the process as well as the results. It is not a chronology
More informationPolicy on the Standardisation of Documentation
Policy on the Standardisation of Documentation Policy Number Target Audience Approving Committee IMTD001 CCG Board members and staff CCG Executive Date Approved November 2013 Last Review Date July 2016
More informationectd in Canada Ginette Larocque, Purdue Pharma Canada August 23, 2016
ectd in Canada Ginette Larocque, Purdue Pharma Canada August 23, 2016 AGENDA Eligibility for Filing in ectd Format ectd Mandatory? Structure and Content LCM Table and HC-SC 3011 Form Info Module 1 Administrative
More informationINTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE
USER GUIDE Use of EDQM terminologies for Dose Forms and Routes of Administration for Individual Case Safety Reports in E2B(R3) message Version 1.0, 16 November 2017 Page 1 of 8 Document History Date of
More informationPreparing for FDA Mandated ectd Submissions
Preparing for FDA Mandated ectd Submissions Outsourcing in Clinical Trials West Coast 2016 11 Feb 2016 2 Agenda Introduction FDA Regulatory Background FDA Timetable International ectd What is an ectd Options
More informationIntroduction to the Points to Consider Documents. MedDRA trademark is owned by IFPMA on behalf of ICH
Introduction to the Points to Consider Documents MedDRA trademark is owned by IFPMA on behalf of ICH MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical
More informationM2 Glossary of Terms and Abbreviations
M2 Glossary of Terms and Abbreviations 11 June 2015 M2: Electronic Standards for the Transfer of Regulatory Information Updated at ICH Expert Working Group meeting, Fukuoka, June 2015 Definitions... 2
More informationEudraVigilance Release Notes v.1.13
24 April 2018 EMA/253902/2018 Information Management 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website
More informationAPI documentation from the perspective of WHO-PQP
API documentation from the perspective of WHO-PQP Antony Fake PhD WHO Medicines Prequalification Programme 1 API documentation 3.2.S.3.2 from Impurities, the perspective of WHO PQP Malaysia, Mumbai, 29
More informationRAISING THE BAR FOR REGULATORY SUBMISSION DOCUMENT QUALITY: A Collaborative, Transitional Approach
RAISING THE BAR FOR REGULATORY SUBMISSION DOCUMENT QUALITY: A Collaborative, Transitional Approach Regulatory Affairs Operations teams rely heavily upon the Medical Writing Community for the delivery of
More informationMock-ups checklist - Guidance for checking mock-ups
24 March 2014 EMA/102667/2014 Veterinary Medicines Division Mock-ups checklist - Guidance for checking mock-ups This guidance should be read in conjunction with: the guideline on the packaging information
More informationWHODrug B3- and C3-formats
2017 WHODrug s Implementation Guide November 2017 INSPIRE. ENGAGE. TRANSFORM. s Table of contents 1. Introduction... 3 2. Background... 3 3. Implementation timeline... 4 4. Description of the B3/C3 formats...
More informationQuality Overall Summary Chemical Entities Clinical Trial Application Phase III QOS - CTA GRP(PQ)-01-1(v1): Date 2008/11/12
Therapeutic Products Directorate To: [Name], Director, Office of Clinical Trials Security Classification: HC Protected From: [Name], Manager, Clinical Trials Quality Division, Office of Clinical Trials
More informationSmPC and. & New QRD. Spanish Medicines Agency (AEMPS)
SmPC and Labelling User Testing & New QRD template Blanca García-Ochoa Martín Spanish Medicines Agency (AEMPS) Legal framework Directive 2001/83/EC of the European Parliament and of the Council of 6 November
More informationPMS Iteration 1: analysis of the data efforts & value results and recommendation on the scope
PMS Iteration 1: analysis of the data efforts & value results and recommendation on the scope EU ISO IDMP Task Force 19 February 2016 Presented by Ilaria Del Seppia Data Standardisation and Analytics,
More informationectd Next Major Version / Regulated Product Submission
ectd Next Major Version / Regulated Product Submission Trusted ectd Solutions At GlobalSubmit, we re not only thought leaders, we re trusted advisors to the FDA, to our clients and to agencies worldwide.
More informationMDSRC , November, 2017 Wah/Pakistan. Template for Abstract Submission
Template for Abstract Submission A single page Abstract of the following pattern has to be submitted by the participating students along with scanned copy of duly filled registration form within the due
More informationThe WIN applies to the Vet Applications team in the Veterinary Regulatory and Organisational Support service (V-VM-ROS).
Work instructions Title: Handling of Veterinary e-submissions Applies to: Veterinary applications team Status: PUBLIC Document no.: WIN/V/4062 Lead Author Approver Effective Date: 18-JUL-16 Name: Dorota
More informationTITLE. Issuance type, number, Title, Publication Date
ACTION OFFICER (AO) NOTES 1. The DoDEA Issuances Standards is the guiding document for the structure and composition of DoDEA issuances. References in this document are referring you to the DoDEA Issuance
More informationResearch in Ireland Conference (THRIC)
12 th Annual Tourism and Hospitality Research in Ireland Conference (THRIC) SUBMISSION GUIDELINES ABSTRACTS AND PAPERS IMPORTANT DATES Conference Notification/Abstract Call 9 th November 2015 Extended
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL GUIDANCE FOR THE SUBMISSION OF REGULATORY INFORMATION IN ectd FORMAT This guideline is intended to provide recommendations to applicants wishing to submit applications for the
More informationCase Study Update on Structured Content Approaches at Genzyme
Case Study Update on Structured Content Approaches at Genzyme Monica Mehta Director, Regulatory Operations Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the
More informationEMEA IMPLEMENTATION OF ELECTRONIC ONLY SUBMISSION AND ectd SUBMISSION:
European Medicines Agency Evaluation of Medicines for Human Use London, 20th July 2008 EMEA/596881/2007 v0.4 EMEA IMPLEMENTATION OF ELECTRONIC ONLY SUBMISSION AND ectd SUBMISSION: QUESTIONS AND ANSWERS
More informationAll the documents related to the EU-RMP Annex 1 activities are stored at the following locations:
Work instructions Title: EU-RMP annex 1: validation Applies to: Risk Management Section Status: PUBLIC Document no.: WIN/H/3292 Lead Author Approver Effective Date: 04-FEB-11 Name: Daniel Becker Name:
More informationStandard operating procedure
Standard operating procedure Title: of medicinal products Status: PUBLIC Document no.: SOP/INSP/2000 Lead author Approver Effective date: 03-APR-12 Name: Camelia Manta Name: Fergus Sweeney Review date:
More informationSUBMISSION OF COMMENTS ON
04 Sep 2009 SUBMISSION OF COMMENTS ON Detailed guidance for the request for authorisation of a clinical trial on a medicinal product for human use to the competent authorities, notification of substantial
More informationextended EudraVigilance Medicinal Product Dictionary (XEVMPD) e-learning
extended EudraVigilance Medicinal Product Dictionary (XEVMPD) e-learning Session 3: Database Architecture Version 5.3 An agency of the European Union Roles of the XEVMPD in the EV System (1) The roles
More informationINCOSE IS2018 Paper Manuscript Instructions
IMPORTANT! As was the case for IS 2017 a Double-Blind Peer Review process will again be used. This means that the identity of the reviewer will be concealed from the author and the author s identity will
More informationTITLE. Issuance type, number, Title, Publication Date
ACTION OFFICER (AO) NOTES 1. The DoDEA Issuances Standards is the guiding document for the structure and composition of DoDEA issuances. Citations in this document refer to the DoDEA Issuance Standards
More informationUpdate of ectd Module 1 specification for South Africa V2.0
Update of ectd Module 1 specification for South Africa V2.0 Dr. Silke Nolkemper, Senior Business Consultant Christine Hirt, Managing Consultant Pretoria Copyright 2016 EXTEDO. All rights reserved. 2 New
More informationFORMAT & TYPING GUIDE
FORMAT & TYPING GUIDE for CEATI Reports updated March 2018 Timeline of a Report Pre-Writing As you sit down to write the report, ensure you begin by downloading the most recent CEATI template at www.ceati.com/rfps.
More informationJournal Text Styles:
Journal Text Styles: International Journal of Work-Integrated Learning Karsten Zegwaard 16 February, 2018 Each journal develops their own style. A journal style is important for the journal s professional
More information